Jatenzo Manufacturer Bridge Programs: How to Get Oral Testosterone Cheaper in 2026

What Is Jatenzo and Why Does It Cost So Much?

Jatenzo is the first oral testosterone replacement therapy approved by the FDA for adult men with hypogonadism caused by a medical condition, a category the FDA label specifies as primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired). The FDA approved Jatenzo on March 27, 2019. [1]

Why the Price Is High

Brand-name oral testosterone carries a premium because no generic oral testosterone undecanoate is currently FDA-approved in the United States. Testosterone itself is a Schedule III controlled substance under the Controlled Substances Act, which adds dispensing complexity and compliance costs that pharmacies pass on to patients. [2]

The drug's dosing schedule, twice daily with a meal containing at least 15 grams of fat, also means patients consume 60 capsules per month, raising the per-unit manufacturing cost compared with injectable or transdermal formulations. A 2022 analysis in the Journal of Clinical Endocrinology and Metabolism found that annual direct pharmacy costs for branded oral androgen therapies in the United States averaged $8,400, roughly three times the cost of intramuscular testosterone cypionate. [3]

The Clinical Case for Jatenzo Over Cheaper Alternatives

Testosterone cypionate injections retail for under $30 per month at most pharmacies. Prescribers and patients who choose Jatenzo despite the cost difference usually do so because injections produce supraphysiologic peaks followed by troughs, a pattern associated with mood fluctuation and erythrocytosis. [4]

The Phase 3 JATENZO-1 trial (N=166) showed that 87% of men achieved a mean total testosterone in the normal range (300 to 1,000 ng/dL) over 13 weeks of twice-daily oral dosing. [5] That pharmacokinetic profile, without the peak-and-trough swings, is the primary clinical rationale for the higher price. Hematocrit elevation still occurred in 5% of subjects, a rate lower than that reported for injectable cypionate in comparative pharmacokinetic work. [6]

How Tolmar's Manufacturer Bridge Program Works

Manufacturer bridge programs are short-term free or heavily discounted drug supplies intended to cover the gap between a new prescription and insurance approval, usually 30 to 90 days. Tolmar has offered this mechanism for Jatenzo since shortly after launch.

Who Qualifies

Bridge eligibility in 2026 typically requires all of the following:

• A valid prescription from a licensed U.S. Prescriber
• A confirmed diagnosis of hypogonadism with documented serum testosterone <300 ng/dL on two morning measurements (consistent with Endocrine Society guideline criteria) [7]
• Commercial insurance coverage that has either not yet processed a prior authorization or has issued a first-level denial under appeal
• No active Medicare, Medicaid, or other federal or state government insurance

The income threshold for bridge programs differs from patient assistance programs. Bridge programs generally have no income test; they exist purely to prevent a coverage gap during the PA process.

How to Enroll

1. Ask your prescriber or their office staff to submit a Jatenzo Prior Authorization request to your insurer at the time of the initial prescription.
2. Contact Tolmar's patient services line (verify the current number at Tolmar.com, as contact details change) and request the bridge supply simultaneously.
3. Provide proof of the pending PA. Tolmar typically ships a 30-day bridge supply within five to seven business days.
4. Once your PA is approved, transition to the savings card program (see below) or standard insurance coverage.

What the Bridge Covers

Bridge supplies are free of charge during the PA review period. Tolmar does not guarantee bridge availability in perpetuity; program terms have changed at least twice since 2019, which is why confirming current terms directly with Tolmar before the first fill matters.

The Jatenzo Savings Card Program

The savings card (sometimes called a copay card or copay assistance card) is the primary ongoing cost-reduction tool for commercially insured patients who have successfully obtained prior authorization.

Current Savings Structure

As of early 2026, Tolmar's savings card program has allowed eligible patients to pay as little as $0 to $60 per month, depending on their insurance tier. The maximum monthly benefit cap and annual benefit cap fluctuate; Tolmar has previously set an annual cap of $3,600. Verify the current cap at JatenzoSavings.com or through Tolmar's patient services line before assuming these figures apply to your plan.

Eligibility Rules

Commercial insurance is required. The savings card cannot be used by patients whose prescriptions are reimbursed, in whole or in part, by Medicare Part D, Medicaid, TRICARE, or any other government-funded program. This restriction exists because federal anti-kickback statutes prohibit manufacturer coupons from applying to federally funded prescriptions. [8]

Patients with Medicare Part D who also have private employer coverage as a secondary payer may wish to consult a benefits coordinator, because using the card against the commercial secondary policy may be permissible, but this is a fact-specific determination.

How to Activate the Card

Savings cards are available through three channels:

1. Tolmar's official Jatenzo website (enrollment form with real-time eligibility check)
2. Your prescriber's office, which may have printed activation codes
3. Some specialty pharmacies, particularly those with established Tolmar contracts

After activation, present the card (physical or digital) at the pharmacy counter alongside your insurance card. The pharmacy submits both claims in sequence; the savings card covers the remaining patient cost after insurance adjudicates.

Patient Assistance Program for Uninsured Patients

Patients with no insurance or with insurance that has exhausted appeals may qualify for Tolmar's Patient Assistance Program (PAP), which provides Jatenzo at no cost.

Income and Documentation Requirements

PAP programs for branded testosterone products typically require household income at or below 400% of the federal poverty level, proof of income (recent tax returns or pay stubs), proof of U.S. Residency, and a prescriber attestation confirming medical necessity. [9]

The 400% FPL threshold in 2026 corresponds to approximately $60,240 for a single-person household, based on 2025 HHS poverty guidelines updated annually. [10]

Application Timeline

PAP applications typically take two to four weeks to process. Patients needing medication during that window should ask their prescriber about a bridge supply (described above) or a 30-day starter sample if the office carries them.

Prior Authorization Strategy: Increasing Approval Odds

Most commercial payers in 2026 require prior authorization for Jatenzo and apply step-therapy criteria, meaning they want documentation that the patient tried a cheaper testosterone formulation first. [11]

What Payers Typically Require

• Two fasting morning serum total testosterone measurements <300 ng/dL (drawn before 10 a.m. Per Endocrine Society guidelines) [7]
• Diagnosis code consistent with hypogonadism (ICD-10-CM E29.1 for testicular hypofunction)
• Clinical rationale for oral over injectable or transdermal formulations
• Failure, intolerance, or contraindication to at least one generic testosterone product in many plans

Writing a Stronger PA Letter

The Endocrine Society's 2018 clinical practice guideline states: "We recommend against a general population screening; we recommend making the diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels." [7] Citing this language in the PA letter, paired with the patient's specific symptom burden (fatigue, decreased libido, erectile dysfunction, loss of muscle mass), strengthens the medical necessity argument.

Prescribers should also document any contraindication to injections (needle phobia meeting clinical criteria, coagulopathy, patient refusal with documented counseling) or intolerance to transdermal formulations (contact dermatitis, skin transfer risk to a partner or child). [12]

The Three-Level Appeal Process

If the initial PA is denied:

1. First-level internal appeal. Submit within 30 days. Include updated lab values and the full clinical note.
2. Second-level appeal or peer-to-peer review. Request a phone call between your prescriber and the payer's medical director. Prescriber-to-prescriber conversations resolve approximately 30 to 40% of second-level denials for branded testosterone products, based on specialty pharmacy outcomes data.
3. External independent review. If the insurer's internal process fails, most states require access to an independent review organization under the ACA. The IRO decision is binding on the insurer in 44 states. [13]

How to Get Jatenzo Cheaper Without Manufacturer Programs

Manufacturer programs are not the only cost-reduction pathway. Several additional strategies apply in 2026.

GoodRx and Cash-Pay Discount Services

GoodRx, RxSaver, and similar pharmacy benefit services negotiate cash-pay rates with pharmacy chains. Cash-pay prices for Jatenzo at major chains have ranged from $580 to $840 for a 30-day supply in early 2026. This is not cheaper than a fully adjudicated insurance claim, but it may be cheaper than a high-deductible plan's rate before the deductible is met.

Patients using a savings card must choose between the savings card and GoodRx at the point of sale; pharmacies typically cannot stack both against the same claim.

Specialty Pharmacy Contracting

Some specialty pharmacies have direct purchasing agreements with Tolmar that result in lower acquisition costs than retail chains. Asking your prescriber to route the prescription to a Tolmar-preferred specialty pharmacy may reduce your copay tier under insurance even before the savings card is applied.

340B Pharmacies

Patients receiving care at federally qualified health centers (FQHCs) or other 340B-covered entities may access Jatenzo at 340B contract pricing, which can be substantially below retail. [14] Eligibility depends on the patient receiving care at the covered entity, not merely filling at its pharmacy.

HSA and FSA Accounts

Jatenzo is a prescription medication, making it an eligible expense under both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) under IRS Publication 502. [15] Using pre-tax dollars effectively reduces the net cost by the patient's marginal tax rate. For a patient in the 22% federal bracket paying $700 per month, the after-tax cost drops to approximately $546.

HSA funds can also be used alongside insurance and the savings card to cover any remaining out-of-pocket amount after both have been applied.

Cardiovascular Safety Context Prescribers and Patients Should Know

Access decisions should always account for clinical suitability. Jatenzo's FDA label carries a boxed warning for increases in blood pressure, and the label states that Jatenzo is not recommended in men with uncontrolled hypertension. [1]

Blood Pressure Data from JATENZO-1

In the Phase 3 trial, mean systolic blood pressure increased by 3.7 mmHg and mean diastolic blood pressure increased by 2.3 mmHg over 13 weeks. [5] Roughly 5.8% of subjects required initiation or adjustment of antihypertensive medications. These numbers matter when selecting a patient for oral vs. Alternative formulations.

Cardiovascular Risk and the FDA

The FDA issued a Drug Safety Communication in 2015 noting that the cardiovascular risks of testosterone therapy had not been established at that time. [16] The subsequent TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement in men with hypogonadism and established cardiovascular risk factors did not increase major adverse cardiovascular events (MACE) at a median follow-up of 33 months (hazard ratio 0.96; 95% CI 0.78 to 1.17). [17] That trial used a transdermal formulation; direct extrapolation to oral testosterone undecanoate requires caution because of Jatenzo's blood pressure signal.

Prescribers should monitor blood pressure at 3 months after starting Jatenzo, then periodically thereafter, consistent with the FDA label recommendation. [1]

Monitoring Requirements That Affect Total Cost of Care

The Endocrine Society guideline recommends checking serum testosterone three to six months after initiation, then annually once stable. [7] Hematocrit should be checked at three months and six months in the first year, then annually. [7]

Lab Costs Add Up

A standard TRT monitoring panel (total testosterone, free testosterone, hematocrit, PSA, and comprehensive metabolic panel) costs $150, $350 out of pocket at a cash-pay lab. Patients optimizing total cost should factor lab frequency into their annual Jatenzo budget, not just the drug itself.

Serum testosterone drawn for Jatenzo should be timed to a morning sample taken approximately six hours after the morning dose, per the FDA label, because peak levels occur around that point. [1] Mis-timed labs frequently produce falsely reassuring or falsely low results that trigger unnecessary dose adjustments.

Cardiovascular Monitoring

Given the blood pressure signal, a home blood pressure cuff (HSA/FSA eligible) is a low-cost addition to any Jatenzo monitoring plan. Patients with baseline hypertension should measure blood pressure weekly for the first 90 days.

Compounded Oral Testosterone: A Note on Alternatives

Some compounding pharmacies offer oral testosterone in a lipid-based formulation, sometimes labeled as "oral testosterone undecanoate" or "oral testosterone cypionate." These preparations are not FDA-approved and are not equivalent to Jatenzo. [18]

The FDA's 2020 guidance on compounding clarifies that drugs available as FDA-approved products (such as testosterone) face restrictions on compounding for individual patients under the FDCA Section 503A. [18] A prescriber must document a specific clinical reason the commercial product cannot be used. Cost alone is generally not considered a valid 503A basis.

Compounded oral androgens also lack the pharmacokinetic data that supports Jatenzo's dosing schedule. Bioavailability can vary significantly across compounding batches, creating unpredictable serum testosterone levels. [19]